Zhixiang Jintai Initiates Phase III Clinical Trial for GR1802 Injection in Treating Allergic Rhinitis

2025-08-13 / Read about 0 minute

Author：小编

Following consultations with the Center for Drug Evaluation at the National Medical Products Administration, Zhixiang Jintai has officially commenced the Phase III clinical trial of GR1802 injection for the treatment of allergic rhinitis. GR1802, a recombinant fully human anti-IL-4Rα monoclonal antibody developed by the company, has secured clinical trial approvals for a broad range of indications, encompassing moderate-to-severe atopic dermatitis, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, asthma, and atopic dermatitis in children and adolescents. Notably, only two drugs targeting the same mechanism have been approved for market in China to date.

Previous page：Trump Family Amasses $4.5 Billion through Cryptocu...

Next page：Hong Kong Stocks Update: Hengrui Medicine Jumps Ov...

Return to List

Hot Reading

2 day ago

Elon Musk's Grok AI Spread Ludicrous Misinformation After Charlie Kirk's Shooting, Saying Kirk Survived and Video Was Fake

2 day ago

FTC launches inquiry into AI chatbot companions from Meta, OpenAI, and others

2 day ago

Financial Experts Concerned That Driving Users Into Psychosis Will Be Bad for AI Investments

2 day ago

OpenAI and Microsoft sign preliminary deal to revise partnership terms